ZNF207抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: HEPG2 and Hela cell lysates, Primary antibody: P02255(ZNF207 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P02255(ZNF207 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

**Background of ZNF207 Antibody**

ZNF207 (Zinc Finger Protein 207) is a member of the zinc finger protein family, characterized by conserved C2H2-type zinc finger domains involved in nucleic acid binding and transcriptional regulation. It plays roles in cellular processes such as proliferation, differentiation, and cell cycle regulation. Studies suggest ZNF207 participates in mitotic exit by interacting with components of the chromosomal passenger complex (CPC) and regulating Aurora B kinase activity. Dysregulation of ZNF207 has been linked to cancers, including hepatocellular carcinoma and breast cancer, where it may act as an oncogene by promoting cell survival or genomic instability.

Antibodies targeting ZNF207 are essential tools for studying its expression, localization, and function. They are commonly used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect endogenous ZNF207 protein levels in tissues or cultured cells. Specific antibodies can distinguish between isoforms or post-translationally modified forms, aiding in mechanistic studies. Commercial ZNF207 antibodies are typically raised against immunogenic epitopes, such as the N-terminal BTB/POZ domain or C-terminal zinc finger regions. Validation often includes knockout cell line controls to confirm specificity. Reliable ZNF207 antibodies support research into its role in development, disease, and potential therapeutic targeting.